S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in
TSE:ASP

Acerus Pharmaceuticals Stock Forecast, Price & News

C$0.06
0.00 (0.00 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
C$0.05
Now: C$0.06
C$0.06
50-Day Range
C$0.04
MA: C$0.05
C$0.06
52-Week Range
C$0.03
Now: C$0.06
C$0.09
Volume28,300 shs
Average Volume287,107 shs
Market CapitalizationC$84.57 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. In addition, the company provides TriVair technology platform that offer applications for pulmonary and nasal pharmaceutical medications. Acerus Pharmaceuticals Corporation sells products through its salesforce in the United States; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.
Acerus Pharmaceuticals logo

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone416-679-0771
Employees11
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$1.33 million
Cash FlowC$0.01 per share

Profitability

Miscellaneous

Outstanding Shares1,537,588,000
Market CapC$84.57 million
Next Earnings Date3/2/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.50 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
C$0.06
0.00 (0.00 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ASP News and Ratings via Email

Sign-up to receive the latest news and ratings for ASP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Acerus Pharmaceuticals (TSE:ASP) Frequently Asked Questions

What stocks does MarketBeat like better than Acerus Pharmaceuticals?

Wall Street analysts have given Acerus Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Acerus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Acerus Pharmaceuticals' next earnings date?

Acerus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Acerus Pharmaceuticals
.

How has Acerus Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Acerus Pharmaceuticals' stock was trading at C$0.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ASP shares have increased by 22.2% and is now trading at C$0.06.
View which stocks have been most impacted by COVID-19
.

Who are Acerus Pharmaceuticals' key executives?

Acerus Pharmaceuticals' management team includes the following people:
  • Mr. Edward Gudaitis, Pres, CEO & Director
  • Mr. Robert M. Motz, Chief Financial Officer
  • Mr. Philippe Savard, VP, Gen. Counsel & Corp. Sec.
  • Mr. Gavin Damstra, Sr. VP of International Commercial
  • Mr. Chris Witty, Investor Relations
  • Dr. Christopher Sorli Ph.D., M.D., F.A.C.E., Chief Medical Officer
  • Mr. Kevin Thomas Hickey, Sr. VP of US Commercial
  • Mr. Hubert Tomasz Czerwinski, Pres of Acerus Pharmaceuticals SRL

Who are some of Acerus Pharmaceuticals' key competitors?

What other stocks do shareholders of Acerus Pharmaceuticals own?

What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ASP."

How do I buy shares of Acerus Pharmaceuticals?

Shares of ASP and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Acerus Pharmaceuticals' stock price today?

One share of ASP stock can currently be purchased for approximately C$0.06.

How much money does Acerus Pharmaceuticals make?

Acerus Pharmaceuticals has a market capitalization of C$84.57 million and generates C$1.33 million in revenue each year.

How many employees does Acerus Pharmaceuticals have?

Acerus Pharmaceuticals employs 11 workers across the globe.

What is Acerus Pharmaceuticals' official website?

The official website for Acerus Pharmaceuticals is www.aceruspharma.com.

How can I contact Acerus Pharmaceuticals?

The company can be reached via phone at 416-679-0771.


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.